Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Stoll

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
Anti-Cancer Drugs|October 14, 2005
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studiesWen-Zhen Gu, Ingrid Joseph, Yi-Chun Wang, et al.
Communications Chemistry|August 16, 2024
Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complexQi Hao, Manoj K Rathinaswamy, Kelly L Klinge, et al.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Journal of Medicinal Chemistry|December 30, 2020
Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug DesignJustin D Dietrich, Kenton L Longenecker, Noel S Wilson, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Molecular Cancer Therapeutics|June 16, 2005
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivoYan Luo, Alexander R Shoemaker, Xuesong Liu, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
Anti-Cancer Drugs|October 14, 2005
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studiesWen-Zhen Gu, Ingrid Joseph, Yi-Chun Wang, et al.
Communications Chemistry|August 16, 2024
Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complexQi Hao, Manoj K Rathinaswamy, Kelly L Klinge, et al.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Journal of Medicinal Chemistry|December 30, 2020
Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug DesignJustin D Dietrich, Kenton L Longenecker, Noel S Wilson, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Molecular Cancer Therapeutics|June 16, 2005
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivoYan Luo, Alexander R Shoemaker, Xuesong Liu, et al.
Pageof 17